Success Metrics

Clinical Success Rate
95.0%

Based on 19 completed trials

Completion Rate
95%(19/20)
Active Trials
1(3%)
Results Posted
16%(3 trials)
Terminated
1(3%)

Phase Distribution

Ph not_applicable
14
42%
Ph phase_3
5
15%
Ph early_phase_1
1
3%
Ph phase_2
3
9%
Ph phase_4
9
27%

Phase Distribution

1

Early Stage

3

Mid Stage

14

Late Stage

Phase Distribution32 total trials
Early Phase 1First-in-human
1(3.1%)
Phase 2Efficacy & side effects
3(9.4%)
Phase 3Large-scale testing
5(15.6%)
Phase 4Post-market surveillance
9(28.1%)
N/ANon-phased studies
14(43.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

95.0%

19 of 20 finished

Non-Completion Rate

5.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

33

all time

Status Distribution
Active(1)
Completed(19)
Terminated(1)
Other(12)

Detailed Status

Completed19
unknown12
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
33
Active
1
Success Rate
95.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (3.1%)
Phase 23 (9.4%)
Phase 35 (15.6%)
Phase 49 (28.1%)
N/A14 (43.8%)

Trials by Status

completed1958%
unknown1236%
recruiting13%
terminated13%

Recent Activity

Clinical Trials (33)

Showing 20 of 33 trialsScroll for more
NCT02612649

Special Drug Use Surveillance of Irribow in Female Patients

Completed
NCT06166615Phase 2

The Safety and Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Fecal Incontinence

Unknown
NCT05577845Not Applicable

5-HT3 Receptor Antagonist (Ramosetron) vs Loperamide for the Treatment of Low Anterior Resection Syndrome(RALARS)

Recruiting
NCT04297293Phase 4

Ramosetron OD Tablet and Postdischarge Nausea and Vomiting

Unknown
NCT03232125Not Applicable

Effect of Ramosetron on Heart Rate-corrected QT Interval During Robot-assisted Laparoscopic Prostatectomy With Steep Trendelenburg Position

Completed
NCT02625181Not Applicable

Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis

Completed
NCT03017222Not Applicable

Therapeutic Efficacy of Ramosetron for Treatment of Established PONV After Laparoscopic Surgery

Completed
NCT03409835Not Applicable

Effect of Ramosetron on Post-discharge Nausea and Vomiting

Unknown
NCT03278522Phase 4

Ramosetron Pre-treatment for PONV and QT Prolongation

Completed
NCT02480088Phase 4

Comparison of Palonosetron and Ramosetron for Preventing Patient-controlled Analgesia Related Nausea and Vomiting Following Spine Surgery; Association With ABCB1 Polymorphism

Completed
NCT02597907Not Applicable

Postoperative Nausea and Vomiting: Ramosetron Plus Aprepitant vs Palonosetron Plus Aprepitant

Completed
NCT00272285Phase 3

A Study of Ramosetron Plus DX, Dexamethasone, Compared to Granisetron Plus DX for the Prevention of Vomiting and Nausea

Completed
NCT02849483Phase 4

Effect of Ramosetron on Bowel Motility After Gynecological Surgery

Unknown
NCT02869984Early Phase 1

Clinical Trial Assessing 5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Anterior Resection Syndrome

Unknown
NCT02830906Phase 3

Effect of Ramosetron in Prevention of Intrathecal Morphine Induced Nausea and Vomiting

Completed
NCT01806948Phase 2

Efficacy Study of Antiemetics to Reduce Postoperative Nausea and Vomiting

Completed
NCT02416115Not Applicable

Anti Emetic Efficacy of Combination of Ramosetron and Premixture of Naloxone With Patient-controlled Analgesia

Completed
NCT02617121Not Applicable

The Effects of Gabapentin and Ramosetron on Postoperative Nausea and Vomiting in Laparoscopic Gynecological Surgery

Unknown
NCT02139241Not Applicable

The Efficacy and Safety of Ramosetron in Patients Undergoing Off Pump Coronary Artery Bypass Surgery

Completed
NCT02604797Not Applicable

Analgesia Effects of Nalbuphine vs Sulfentanil

Unknown

Drug Details

Intervention Type
DRUG
Total Trials
33